— Know what they know.
Not Investment Advice

KZIA NASDAQ

Kazia Therapeutics Ltd ADR
1W: -3.1% 1M: -26.5% 3M: -29.1% YTD: +85.4% 1Y: +35.3% 3Y: -82.0% 5Y: -98.3%
$9.27
-0.20 (-2.11%)
 
Weekly Expected Move ±9.3%
$8 $8 $9 $10 $11
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 33 · $15.0M mcap · 2M float · 15.18% daily turnover · Short 50% of daily vol

Balance Sheet Trends

Total Assets
$6M -71.9% ▼
5Y CAGR: -23.5%
Total Liabilities
$14M -54.6% ▼
5Y CAGR: +9.9%
Shareholders Equity
-$8M +17.1% ▲
Cash & Investments
$4M +162.2% ▲
5Y CAGR: -13.1%
Total Debt
$396K -37.5% ▼
Net Debt
-$4M -286.0% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$28M$7M$5M$2M$4M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$28M$7M$5M$2M$4M
Net Receivables$0$51K$105K$133K$90K
Inventory$0$0$0$0$0
Other Current Assets$84K$0$0$0$0
Total Current Assets$29M$9M$11M$6M$5M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$22M$19M$17M$15M$1M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$7M$7M$43K$40K$40K
Total Non-Current Assets$29M$26M$17M$15M$1M
Total Assets$58M$36M$28M$22M$6M
— Liabilities —
Accounts Payable$2M$2M$857K$5M$6M
Short-Term Debt$0$2M$2M$634K$396K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$3M$1M$1M$10M$4M
Total Current Liabilities$8M$7M$8M$26M$14M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$12M$8M$6M$4M$37K
Total Non-Current Liabilities$12M$11M$8M$6M$309K
Total Liabilities$20M$18M$16M$32M$14M
— Equity —
Common Stock$80M$84M$97M$102M$123M
Retained Earnings-$44M-$69M-$89M-$115M-$135M
Accumulated OCI$2M$2M$4M$3M$3M
Total Stockholders Equity$38M$18M$12M-$10M-$8M
Total Liabilities & Equity$58M$36M$28M$22M$6M
— Key Metrics —
Total Debt$0$2M$2M$634K$396K
Net Debt-$28M-$6M-$3M-$1M-$4M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms